Table 6.
Selected inhibitors target in SUMO pathway.
| Compound ID | Description | Stage | |
|---|---|---|---|
| E1 | TAK-981 (Subasumstat) | The first-in-Class SAE Inhibitor | Phase I/II trials (https://clinicaltrials.gov/ct2/show/NCT03648372, accessed on 1 March 2022) |
| Ginkgolic acid, davidiin, tannic acid, kerriamycin B, Pyrazole, and thiazole urea containing Cpds | SAE inhibitor | Preclinical [93,94,95,96,112] | |
| E2 | 2-D08, Spectomyin B | UBC9 inhibitor | Preclinical [101,102,103,104,105,106] |
| SENP | GN6958, Triterpenoids, Monomeric Ic | SENP1 inhibitor | Preclinical [108,110,111] |
| JCP666 and its analogues | SENP1/2 inhibitor | Preclinical [113] | |
| SUMO-1-VS, Ebselen and 6-thioguanine | SENP2 inhibitor | Preclinical [114,115] | |
| SI2 | SENP1/2/3 inhibitor | Preclinical [109] | |
| SPI-01 | SENP1/2/7 inhibitor | Preclinical [109] | |
| VEA499/VEA561 | SENP1/2/6/7 inhibitor | Preclinical [113] |
Abbreviations: Cpd, compounds; SAE, SUMO-activating enzyme; UBC9, ubiquitin-conjugating enzyme 9; SENP, SUMO-specific proteases.